Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:PMN)

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

GlobeNewswire April 9, 2024

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April 

GlobeNewswire April 4, 2024

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

GlobeNewswire April 1, 2024

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

GlobeNewswire March 11, 2024

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

GlobeNewswire February 22, 2024

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

GlobeNewswire January 22, 2024

ProMIS Neurosciences Issues Letter to Shareholders

GlobeNewswire January 8, 2024

ProMIS Neurosciences, Inc. Announces Leadership Transition

GlobeNewswire January 3, 2024

ProMIS Neurosciences Announces Publication on Novel Target for ALS

GlobeNewswire December 20, 2023
View More News ››

Opinion & Analysis (NDAQ:PMN)

Building a Better Covid-19 Antibody Test

Streetwise Reports May 7, 2020

Could There Finally Be an Effective Treatment for Alzheimer's Disease?

Streetwise Reports November 7, 2019

Alzheimer’s Solution Shows Promise after Big Pharma’s Cure Fails

Stockhouse Editorial March 28, 2019

Biotech Releases White Paper on Alzheimer's Disease Candidate

Streetwise Reports August 2, 2018

Preclinical Data for Alzheimer's Therapy to Be Presented at AAIC

Streetwise Reports July 11, 2018

Candidates Targeting Parkinson's Disease and ALS Advance in Discovery Phase

Streetwise Reports June 28, 2018
View More Opinion ››

Bullboard Posts (NDAQ:PMN)

TOXIC OLIGOMERS / JUNE DATA

The incidence of Alzheimer's disease (AD) is growing every day and finding an effective treatment is becoming more vital. Amyloid-β...
goldtech - 14 hours ago

Prothena

Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the...
goldtech - 1 day ago

RE:RE:1A Results/Market Awareness

A deal with a Pharma company that could leverage Promis's platform, Alzhemers might not work out, perhaps ALS , PD, vaccines have a...
farmerlucy - 1 day ago

RE:RE:1A Results/Market Awareness

Yup, 1A unlikely to be a market mover.  I cannot imagine the investor out there sitting on 1a results.   Granted Pfizer made a...
M101 - 1 day ago

RE:1A Results/Market Awareness

I wish you were right but the fact is Promis over the last couple of years has just been testing animals and humans not alzheimers...
farmerlucy - 1 day ago

1A Results/Market Awareness

When the 1A results are released in June the market will begin to put us on their radar screen and news letter writers will comment to...
goldtech - 1 day ago
View more Bullboard ››

Saturn Oil & Gas Inc.

Saturn Oil & Gas Inc.

Saturn Oil & Gas Inc. is a Canada-based energy company. The Company’s focus is to advance the exploration and development of ...
View More »